US 12,215,148 B2
Antigen binding molecule formats
Tong Zhang, New Rochelle, NY (US); Erica Pyles, New City, NY (US); Michael Rosconi, New City, NY (US); Nina Liu, Chappaqua, NY (US); Supriya Patel, Elmsford, NY (US); Eric Smith, New York, NY (US); Andrew Murphy, Croton-on-Hudson, NY (US); Chiayang Lin, Scarsdale, NY (US); and Samuel Davis, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Aug. 7, 2020, as Appl. No. 16/987,487.
Claims priority of provisional application 63/050,483, filed on Jul. 10, 2020.
Claims priority of provisional application 62/884,496, filed on Aug. 8, 2019.
Prior Publication US 2021/0040197 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 47/6845 (2017.08); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 25 Claims
 
1. A method, comprising contacting a target molecule having a molecular weight of less than 100 kDa exclusive of post-translational modifications with an antigen-binding molecule comprising:
(a) a first half antibody comprising in an N- to C-terminal orientation:
(i) a first Fc domain which lacks a Fab domain at its N-terminus; and
(ii) a first Fab domain that binds to the target molecule, the first Fab domain comprising a first heavy chain variable region (VH) associated with a first light chain variable region (VL) on a separate polypeptide chain; and
(b) a second half antibody comprising in an N- to C-terminal orientation:
(i) a second Fc domain which lacks a Fab domain at its N-terminus, the second Fc domain associated with the first Fc domain to form an Fc heterodimer; and
(ii) a second Fab domain that binds to the target molecule, the second Fab domain comprising a second VH associated with a second VL on a separate polypeptide chain.